Continue reading Baxter: Incremental Progress

Baxter: Incremental Progress originally appeared on BloggingStocks on Wed, 30 Mar 2011 17:00:00 EST. Please see our terms for use of feeds.

"We follow an approach to investng that focuses on broadly diversified investments in undervalued stocks for their long-term appreciation potential," says value investor John Buckingham.

The money manager and editor of The Prudent Speculator explains, " Two recently featured ideas -- Abbott Laboratories (ABT) and Baxter International (BAX) -- are among those we feel could serve as a portfolio foundation or as a new ideas for well- diversified holdings.

Continue reading Abbott (ABT) and Baxter (BAX): Healthy Gains

Abbott (ABT) and Baxter (BAX): Healthy Gains originally appeared on BloggingStocks on Tue, 01 Mar 2011 10:00:00 EST. Please see our terms for use of feeds.

I first discussed Baxter International (BAX) here on March 13, 2009, at a price of $51.16, and share have since drifted below $50 after clearing that key, psychological resistance level. The calculation is to maintain the trade, but Baxter needs to show some improvement in the months ahead.

Baxter makes a variety of medical products across three divisions: drugs and vaccines, dialysis equipment, and IV supplies. The 2011 performance likely will be led by continued growth in IV therapies, global injectables and anesthesia products, and renal care (including revenue growth in its peritoneal dialysis product).

Continue reading Baxter's Stock Struggles to Push Through $50

Baxter's Stock Struggles to Push Through $50 originally appeared on BloggingStocks on Sun, 30 Jan 2011 11:10:00 EST. Please see our terms for use of feeds.

Baxter International's (BAX) shares have bumped up against resistance at $60 over the past three months, but I'm reiterating my buy rating for the company's shares, first recommended on March 13, 2009, at a price of $51.16. Here's why:

Versatility remains Baxter's key. Baxter makes a variety of medical products across three divisions, including drugs and vaccines, dialysis equipment, and IV supplies. The company should record a FY2010 revenue increase of 7% to 10%, led by demand for recombinants, plasma proteins, and antibody therapies in its bioscience unit.

Continue reading Baxter International Is Undervalued

Baxter International Is Undervalued originally appeared on BloggingStocks on Mon, 11 Jan 2010 10:00:00 EST. Please see our terms for use of feeds.

"Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam.

In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound.

"We think that investors who got left behind by the first leg of the market rally are struggling to catch up.

Continue reading Turnaround expert targets laggard pharmaceuticals

Turnaround expert targets laggard pharmaceuticals originally appeared on BloggingStocks on Mon, 12 Oct 2009 12:10:00 EST. Please see our terms for use of feeds.

Continue reading Baxter International (BAX) dips on growth estimates

Baxter International (BAX) dips on growth estimates originally appeared on BloggingStocks on Wed, 16 Sep 2009 13:30:00 EST. Please see our terms for use of feeds.

Continue reading Consider Baxter: Its products don't go out of style

Consider Baxter: Its products don't go out of style originally appeared on BloggingStocks on Sat, 18 Jul 2009 15:00:00 EST. Please see our terms for use of feeds.

Continue reading Baxter (BAX) Q1 earnings beat estimates

Baxter (BAX) Q1 earnings beat estimates originally appeared on BloggingStocks on Thu, 16 Apr 2009 14:30:00 EST. Please see our terms for use of feeds.

Alcoa Inc. (NYSE: AA) started off the new earnings season with disappointing results that helped to stifle the recent rally. Was that enough of a sign of what's to come? No, probably not. But the earnings reports start to fly in earnest this week, which should provide a more detailed picture of the state of things.

Analysts surveyed by Thomson Reuters anticipate that some of the biggest names will prove to be holding their own. Google Inc. (NASDAQ: GOOG) is expected to post a profit of $4.91 per share, marginally higher than a year ago, and Johnson & Johnson's (NYSE: JNJ) expected $1.22 per share profit is slightly lower year over year. Even Mattel Inc.'s (NYSE: MAT) estimated loss of $0.13 per share is the same as in the year-ago period.

Continue reading The week in preview: The new earnings season ramps up

The week in preview: The new earnings season ramps up originally appeared on BloggingStocks on Sun, 12 Apr 2009 12:30:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• The Wall Street Journal reported that the focus of reports of four deaths and 350 allergic reactions to Baxter International Inc's (NYSE: BAX) generic version of the blood thinner drug Heparin, and the ingredients supplied by a Chinese manufacturer, also includes Wisconsin-based Scientific Protein Laboratories, a co-owner of the Chinese manufacturing plant, and majority owned by American Capital Strategies Ltd (NASDAQ: ACAS), a Maryland buyout firm.
• Citigroup Incorporated (NYSE: C) has suspended investors at its CSO Partners hedge fund from withdrawing their money after they attempted to pull more than 30% of the fund's nearly $500M in assets, the Wall Street Journal reported.
• AT&T Inc (NYSE: T) is seeking more revenue from India as it tries to expand its consumer mobile phone operations outside the U.S, the Financial Times reported.

• According to the New York Times, the FDA broke its own rules by approving for sale Baxter International's Heparin without first inspecting a Chinese plant where the drug's key ingredient is made.

Newspaper wrap-up: American Capital Strategies tied to Baxter's Heparin generic problems originally appeared on BloggingStocks on Fri, 15 Feb 2008 08:00:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• The active ingredient in Baxter International Inc's (NYSE: BAX) generic version of the anticlotting drug heparin, under investigation for four deaths and hundreds of bad reactions, was made in China, the Wall Street Journal reported.
• Structured investment vehicles that provide short term debt to fund the purchases of municipal bonds and student loans are under increasing pressure, according to the Wall Street Journal's "Heard on the Street". Citigroup Incorporated (NYSE: C), JP Morgan Chase & Co (NYSE: JPM) and Merrill Lynch & Co Inc (NYSE: MER) are among the banks that could be affected.

• The New York Times reported that Hewlett-Packard Company (NYSE: HPQ) has settled with The New York Times Company (NYSE: NYT) and McGraw Hill Companies Incorporated's (NYSE: MHP) BusinessWeek journalists related to a spying scandal that stemmed from obtaining telephone records. The involved parties did not disclose the amount of the settlement.

• Mike Zafirovski, CEO of Nortel Networks Corporation (NYSE: NT), said the company would examine possible opportunities to be taken over "when they arise." Mr. Zafirovski did not comment on rumors of a Motorola Inc (NYSE: MOT) merger, Reuters reported.

Newspaper wrap-up: Investigated ingredient in Baxter's generic heparin drug made in China originally appeared on BloggingStocks on Thu, 14 Feb 2008 08:00:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Baird initiated Amag Pharmaceuticals (NASDAQ: AMAG) with an Outperform rating and believes concerns regarding ferumoxytol approvability are misplaced.
• JP Morgan assumed coverage of Corn Products (NYSE: CPO) with an Overweight rating and points to the company's growth in emerging markets and improved business economics in its core U.S. market.
• RBC Capital is positive on Alpharma's (NYSE: ALO) Flector opportunity in the U.S. topical NSAID market. The firm started shares with an Outperform rating and $28 target.

• Merrill resumed coverage of Baxter (NYSE: BAX) with a Buy rating.
• Goldman initiated Teradyne (NYSE: TER) with a Neutral rating and $11 target.
• Allianz AG (NYSE: AZ) was initiated with a Buy rating at Societe Generale.

Analyst initiations: AMAG, CPO and ALO originally appeared on BloggingStocks on Mon, 04 Feb 2008 10:50:00 EST. Please see our terms for use of feeds.

In the business world, innvoation leads to longevity. There is a medical products firm in Deerfield, Illinois that was the first manufacturer of commercially prepared intravenous solutions. It was also responsible for such landmark developments as the first container that could store blood for more than a few hours, the first means of separating plasma from whole blood and storing it for future use, and the first disposable total-bypass blood-oxygenator. The company has been in business for 76 years.

Baxter International (NYSE: BAX) is a diversified medical products and services company. It provides devices, pharmaceuticals, and biotechnology for the treatment of hemophilia, immune disorders, cancer, infectious diseases, kidney disease and trauma. The BioScience segment manufactures plasma-based therapies for immune disorders, biosurgery products for hemostasis, and vaccines. The Medication Delivery unit makes intravenous solutions and administration sets. The Renal segment manufactures products for peritoneal dialysis, a home therapy for people with end-stage renal disease. Boston Scientific (NYSEL: BSX) is a major competitor.

Investors were pleased last week, when Citigroup upgraded the shares from "hold" to "buy." Analyst Matthew J. Dodds said the firm can increase its gross margins above Wall Street expectations, a welcome prediction ahead of the Baxter's fourth quarter report (1/24). He also predicted 2008 EPS of $3.21, versus the Street expectation of $3.10.

Continue reading Baxter International (BAX) shares popping from bullish flag consolidation

Baxter International (BAX) shares popping from bullish flag consolidation originally appeared on BloggingStocks on Thu, 17 Jan 2008 14:55:00 EST. Please see our terms for use of feeds.

In the business world, innovation leads to longevity. There is a medical products firm in Deerfield, Illinois, that was the first manufacturer of commercially prepared intravenous solutions. It was also responsible for such landmark developments as the first container that could store blood for more than a few hours, the first means of separating plasma from whole blood and storing it for future use, and the first disposable total-bypass blood-oxygenator. The company has been in business for 76 years.

Baxter International (NYSE: BAX) is a diversified medical products and services firm. It provides devices, pharmaceuticals, and biotechnology for the treatment of hemophilia, immune disorders, cancer, infectious diseases, kidney disease and trauma. The BioScience segment manufactures plasma-based therapies for immune disorders, biosurgery products for hemostasis, and vaccines. The Medication Delivery unit makes intravenous solutions and administration sets. The Renal segment manufactures products for peritoneal dialysis, a home therapy for people with end-stage renal disease. The company has more than 250 facilities in 50 countries around the world. Boston Scientific (NYSE: BSX) is a major competitor.

Continue reading Baxter International (BAX): BAX forms a bullish flag

Baxter International (BAX): BAX forms a bullish flag originally appeared on BloggingStocks on Tue, 23 Oct 2007 13:06:00 EST. Please see our terms for use of feeds.